• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602070)   Today's Articles (527)   Subscriber (49367)
For: Carlson JJ, Chen S, Garrison LP. Performance-Based Risk-Sharing Arrangements: An Updated International Review. Pharmacoeconomics 2017;35:1063-1072. [PMID: 28695544 DOI: 10.1007/s40273-017-0535-z] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Number Cited by Other Article(s)
51
Improving Access to High-Cost Technologies in the Asia Region. Int J Technol Assess Health Care 2019;35:168-175. [PMID: 31122302 DOI: 10.1017/s026646231900031x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
52
Darbà J, Ascanio M. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia. Expert Rev Pharmacoecon Outcomes Res 2019;19:743-748. [PMID: 30821532 DOI: 10.1080/14737167.2019.1587296] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
53
Vella Bonanno P, Bucsics A, Simoens S, Martin AP, Oortwijn W, Gulbinovič J, Rothe C, Timoney A, Ferrario A, Gad M, Salem A, Hoxha I, Sauermann R, Kamusheva M, Dimitrova M, Petrova G, Laius O, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Jakupi A, Bochenek T, Wladysiuk M, Furtado C, Marković-Peković V, Mardare I, Meshkov D, Fürst J, Tomek D, Cortadellas MO, Zara C, Haycox A, Campbell S, Godman B. Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA. Expert Rev Pharmacoecon Outcomes Res 2019;19:251-261. [PMID: 30696372 DOI: 10.1080/14737167.2019.1575730] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
54
Ginsburg GS, Phillips KA. Precision Medicine: From Science To Value. Health Aff (Millwood) 2019;37:694-701. [PMID: 29733705 DOI: 10.1377/hlthaff.2017.1624] [Citation(s) in RCA: 316] [Impact Index Per Article: 63.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
55
Jørgensen J, Kefalas P. Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate. JOURNAL OF MARKET ACCESS & HEALTH POLICY 2019;7:1635842. [PMID: 31303982 PMCID: PMC6609347 DOI: 10.1080/20016689.2019.1635842] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 06/13/2019] [Accepted: 06/21/2019] [Indexed: 05/05/2023]
56
Jørgensen J, Mungapen L, Kefalas P. Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching. JOURNAL OF MARKET ACCESS & HEALTH POLICY 2019;7:1573164. [PMID: 30774785 PMCID: PMC6366432 DOI: 10.1080/20016689.2019.1573164] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Revised: 01/08/2019] [Accepted: 01/11/2019] [Indexed: 05/05/2023]
57
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S, Kurdi A, Gad M, Gulbinovič J, Timoney A, Bochenek T, Salem A, Hoxha I, Sauermann R, Massele A, Guerra AA, Petrova G, Mitkova Z, Achniotou G, Laius O, Sermet C, Selke G, Kourafalos V, Yfantopoulos J, Magnusson E, Joppi R, Oluka M, Kwon HY, Jakupi A, Kalemeera F, Fadare JO, Melien O, Pomorski M, Wladysiuk M, Marković-Peković V, Mardare I, Meshkov D, Novakovic T, Fürst J, Tomek D, Zara C, Diogene E, Meyer JC, Malmström R, Wettermark B, Matsebula Z, Campbell S, Haycox A. Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Front Public Health 2018;6:328. [PMID: 30568938 PMCID: PMC6290038 DOI: 10.3389/fpubh.2018.00328] [Citation(s) in RCA: 88] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 10/26/2018] [Indexed: 01/26/2023]  Open
58
Trosman JR, Weldon CB, Gradishar WJ, Benson AB, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2018;21:1062-1068. [PMID: 30224110 PMCID: PMC6374027 DOI: 10.1016/j.jval.2018.06.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 06/11/2018] [Indexed: 05/16/2023]
59
Antoñanzas F, Rodríguez-Ibeas R, Juárez-Castelló CA. Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails? PHARMACOECONOMICS 2018;36:733-743. [PMID: 29450830 DOI: 10.1007/s40273-018-0619-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
60
Tuffaha HW, Scuffham PA. The Australian Managed Entry Scheme: Are We Getting it Right? PHARMACOECONOMICS 2018;36:555-565. [PMID: 29478116 DOI: 10.1007/s40273-018-0633-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
61
Grimm SE, Strong M, Brennan A, Wailoo AJ. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment. PHARMACOECONOMICS 2017;35:1287-1296. [PMID: 28849538 PMCID: PMC5684269 DOI: 10.1007/s40273-017-0562-9] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
62
Ferrario A, Arāja D, Bochenek T, Čatić T, Dankó D, Dimitrova M, Fürst J, Greičiūtė-Kuprijanov I, Hoxha I, Jakupi A, Laidmäe E, Löblová O, Mardare I, Markovic-Pekovic V, Meshkov D, Novakovic T, Petrova G, Pomorski M, Tomek D, Voncina L, Haycox A, Kanavos P, Vella Bonanno P, Godman B. The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. PHARMACOECONOMICS 2017;35:1271-1285. [PMID: 28836222 PMCID: PMC5684278 DOI: 10.1007/s40273-017-0559-4] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
PrevPage 2 of 2 12Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA